Liver-only mPDAC was modestly enriched for TP53 mutations, MYC amplifications, CDK2NA inactivating alterations, mutations in the SWI/SNF pathway, and SMAD4 inactivating alterations, which impart a more aggressive disease characteristic to the tumor relative to lung-only mPDAC. This evidence concerns the gene SMARCA1 and neoplasm.